Geneticist Announces Congressional Bid

UC Berkeley researcher Michael Eisen says he will run for Senate in 2018.

Written byBob Grant
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, PLOSGeneticist Michael Eisen of the University of California, Berkeley, has been a vocal opponent of Donald Trump. Now, the researcher has announced his intent to run for US Senate. “We can't sit around and hope other people are going to solve our problems for us - time to step up, if you can…,” Eisen posted on his Twitter account on Sunday (January 29) after announcing his senate run last week (January 25).

“Too much of the scientific establishment looks at the government as a bank—that the primary thing we should worry about is can we get the right amount of money out of Congress,” Eisen told Science. “Too few people focus on the fact that science needs to be a partnership with the public for it to thrive.”

Eisen, who told Science that he plans to run as an independent, is perhaps the most recognizable name in a list of other scientists who are considering running for office to combat policies that seem broadly antagonistic to science. The groundswell is partly thanks to 314 Action, an organization run by chemist and former breast cancer researcher Shaughnessy Naughton, who ran for Congress in 2014 and 2016 but lost ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies